Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

Collins, P., Quon, D., Makris, M. orcid.org/0000-0001-7622-7939 et al. (9 more authors) (2017) Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. ISSN 1351-8216

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2017 The Authors. Haemophilia. Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Keywords: efficacy; haemophilia B; IB1001; pharmacokinetics; recombinant factor IX; safety
Dates:
  • Published (online): 17 August 2017
  • Accepted: 17 July 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Cardiovascular Science (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 21 Jul 2017 13:56
Last Modified: 21 Sep 2017 08:19
Published Version: https://doi.org/10.1111/hae.13324
Status: Published online
Publisher: Wiley
Refereed: Yes
Identification Number: https://doi.org/10.1111/hae.13324

Share / Export

Statistics